• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The disclosed invention relates to a topical composition comprising a source of abietic acid or an ester or salt thereof as an active ingredient for use in treatment of perniosis.
    公开号:BE1024364B1
    申请号:E2016/5508
    申请日:2016-06-29
    公开日:2018-02-05
    发明作者:Virginie Noë
    申请人:Holding Tolpoort Bvba；
    IPC主号:
    专利说明:

    Priority date:
    International classification: A61Q 19/00, A61K 8/97, A61K 36/15, A61K 36/48 Application number: BE2016 / 5508
    Date of submission: 29/06/2016
    Holder:
    HOLDING TOLPOORT BVBA
    9800, DEINZE
    Belgium
    Inventor:
    NOË Virginie 9800 DEINZE Belgium
    COMPOSITION FOR TREATMENT OF SKIN DISORDERS
    The described invention relates to a topical composition comprising a source of abietic acid or an ester or salt thereof as an active ingredient for use in treatment of perniosis.
    BELGIAN INVENTION PATENT
    FPS Economy, K.M.O., Self-employed & Energy
    Publication number: 1024364 Filing number: BE2016 / 5508
    Intellectual Property Office International classification: A61Q 19/00 A61K 8/97 A61K 36/15 A61K 36/48
    Date of grant: 05/02/2018
    The Minister of Economy,
    Having regard to the Paris Convention of 20 March 1883 for the Protection of Industrial Property;
    Having regard to the Law of March 28, 1984 on inventive patents, Article 22, for patent applications filed before September 22, 2014;
    Having regard to Title 1 Invention Patents of Book XI of the Economic Law Code, Article XI.24, for patent applications filed from September 22, 2014;
    Having regard to the Royal Decree of 2 December 1986 on the filing, granting and maintenance of inventive patents, Article 28;
    Having regard to the application for an invention patent received by the Intellectual Property Office on 29/06/2016.
    Whereas for patent applications that fall within the scope of Title 1, Book XI, of the Code of Economic Law (hereinafter WER), in accordance with Article XI.19, § 4, second paragraph, of the WER, the granted patent will be limited. to the patent claims for which the novelty search report was prepared, when the patent application is the subject of a novelty search report alleging a lack of unity of invention as referred to in paragraph 1, and when the applicant does not limit his filing and does not file a divisional application in accordance with the search report.
    Decision:
    Article 1
    HOLDING TOLPOORT BVBA, Tolpoortstraat 74, 9800 DEINZE Belgium;
    represented by
    BRANTS Johan Philippe Emile, Pauline Van Pottelsberghelaan 24, 9051, GHENT;
    a Belgian invention patent with a term of 20 years, subject to payment of the annual fees as referred to in Article XI.48, § 1 of the Code of Economic Law, for: COMPOSITION FOR TREATMENT OF SKIN DISEASES.
    INVENTOR (S):
    NOE Virginie, Tolpoortstraat 74, 9800, DEINZE;
    PRIORITY:
    BREAKDOWN:
    Split from basic application: Filing date of the basic application:
    Article 2. - This patent is granted without prior investigation into the patentability of the invention, without warranty of the Merit of the invention, nor of the accuracy of its description and at the risk of the applicant (s).
    Brussels, 05/02/2018,
    With special authorization:
    BE2016 / 5508
    COMPOSITION FOR TREATMENT OF PERNIOSIS
    TECHNICAL DOMAIN
    The present invention relates to a (dermatological) composition for the treatment of irritated or damaged skin, in particular for the treatment of perniosis.
    STATE OF THE ART
    Normally, the skin is kept moist by secretion of sebum and sweat from, respectively, sebaceous and sweat glands present in and on the skin. However, some conditions - atopic dermatitis, skin diseases, immunological diseases, hormone imbalance, drug intake, metabolic diseases, radiation exposure, etc. - can lead to dry and / or irritated skin.
    The term dry skin, Xeroderma or xerosis refers to an abnormal dryness of a patient's skin and is used as a general term for various Symptoms - for example, itching and roughness of the skin - that are caused by such condition. Irritated skin is mainly characterized by redness, sensitivity to touch and is often scaly.
    Usually, in the current state of the art, the dryness or irritation of the skin is prevented by applying a moisturizing composition such as a cream, ointment, lotion, gel, etc. Nevertheless, such composition often only has a temporary effect and it is necessary to apply them regularly which can result in skin allergies and / or side effects. A steroid ointment can - alternatively - have a therapeutic effect, but it can also cause skin atrophy or fungal infections and should therefore be used under strictly limited conditions. The latter still hinders the development of such treatment techniques.
    The term perniosis is the general name for winter hands and / or winter toes. Perniosis is a condition that mainly occurs in the winter months and is caused by the action of the cold on defective bloodstream skin. In cold conditions, the circulation of the vital organs in the body is prioritized and the capillaries in the non-vital parts of the body - such as fingertips and toes - are narrowed to minimize heat loss. As a result, the extremities of the body - mainly fingertips and toes - get less blood flow and become more sensitive to cold. This causes bluish-red, painful and severely itchy swelling of the fingers and / or
    BE2016 / 5508 toes. Although in most cases perniosis is a harmless condition, the patient often experiences severe discomfort.
    The treatment of perniosis - in the current state of the art - often relates to improving blood circulation by taking calcium antagonists or taking exchange baths or a foot sauna. The use of calcium channel blockers produces a large amount of unwanted and systemic side effects, while taking baths or a foot sauna is practically very undesirable.
    In some cases, perniosis can lead to skin cracks. These are painful tears in the skin because the skin is often too dry in winter. The resulting wounds are very sensitive, painful and difficult to treat.
    Damaged skin can be caused by, for example, bumping, falling, burning or chafing the skin and interrupts the barrier function of the skin, which greatly increases the chance of infection and / or inflammation.
    To date, there are no effective means for treating the above mentioned skin conditions. A known problem in the prior art is that there are mainly preventive - and not very effective - compositions, and that there are no known compositions that both repair the skin barrier and moisturize the skin to protect them from further drying.
    SUMMARY OF THE INVENTION
    The present invention in a first aspect contains a composition according to claim 1. In particular, the present invention relates to a composition comprising a source of abietic acid or an ester or salt thereof as an active ingredient, for use in treatment of perniosis
    DETAILED DESCRIPTION
    Unless otherwise defined, all terms used in the description of the invention, including technical and scientific terms, have the meaning generally understood by those skilled in the art of the invention.
    One, de and the in this document refer to both the singular and the plural unless the context clearly assumes otherwise. For example, a segment means one or more than a segment.
    BE2016 / 5508
    The terms include, include, consist of, consist of, include, contain, contain, control, controlling, contents, containing are synonyms and are inclusive or open terms that indicate the presence of what follows, and do not exclude or prevent the presence of other components, features, elements, members, steps, known from or described in the prior art.
    Claiming numerical intervals through the endpoints includes all integers, fractions and / or real numbers between the endpoints, including these endpoints.
    The present invention relates to a topical composition comprising a source of abietic acid or an ester or salt thereof as an active ingredient and the use of such composition in the treatment of dry and / or irritated skin, perniosis, skin splits and / or damaged skin.
    Abietic acid is a diterpene carboxylic acid, which is found, inter alia, in coniferous resin and which is used in the present state of the art in organic syntheses, and - as a component of vegetable resins - in caulking ships, waxing bows of musical instruments, and - after conversion into its glycerol ester - as a base for paints, varnishes and glues. However, the present invention describes a new and inventive use of abietic acid.
    In a first aspect, the present invention relates to a topical composition comprising abietic acid or an ester or salt thereof as the active ingredient. The present invention describes the positive effects of abietic acid on the repair and hydration of affected skin.
    Topical compositions of the present invention can exist in various embodiments.
    The present embodiment concerns a topical composition comprising a source of abietic acid or an ester or salt thereof.
    In a preferred embodiment, a topical composition according to the present invention comprises abietic acid of natural origin. Tests by the inventors show that a natural source of abietic acid works better than a synthetic or pure source of abietic acid. This is most likely due to an interaction between the abietic acid and essential oils or other components present in the natural source.
    BE2016 / 5508
    A topical composition according to the present invention preferably comprises 0.1 to 50 mass% abietic acid, more preferably 0.1 to 25 mass% abietic acid, even more preferably 0.5 to 10 mass% abietic acid, and most preferably 0.5 to 2.5 mass% abietic acid.
    In another embodiment, the present invention includes a topical composition which preferably comprises 0.1 to 50 mass% of a source of abietic acid as the active ingredient, more preferably 0.1 to 25 mass% of a source of abietic acid as the active ingredient, even more preferably 0.5 to 10 mass% of a source of abietic acid as an active ingredient and most preferably 0.5 to 2.5 mass% of a source of abietic acid as an active ingredient.
    In an embodiment of the present invention, the natural source of abietic acid will be a Picea abies resin. In one embodiment, this source can be turpentine (an oleoresin), preferably obtained from conifers. In another preferred form, said resin can be refined into rosin after mining. In another most preferred embodiment, the composition of the present invention includes Poix de Bourgogne (Kremer Pigmente GmbH & Co. KG) as a source of abietic acid.
    In the present invention, the term rosin or rosin refers to a vegetable resin that is recovered from the coniferous resin by heating or distillation. The liquid resin of pine or spruce trees is heated so that volatiles - such as terpenes - evaporate, leaving a transparent yellow to black gelatinous mass. This remainder is called rosin. Although the use of rosin is widespread, the use of rosin in topical compositions is not yet known in the art.
    In the present invention, the term Poix de Bourgogne refers to a natural product that is obtained as a refining product from the resin of Picea abies from the Burgundy region located in the eastern part of France. More specifically, Poix de Bourgogne is produced by melting Picea abies resin and then filtering or distilling the resin.
    A topical composition according to an embodiment of the present invention, in a preferred embodiment comprises one or more pharmaceutically accepted excipients and / or one or more additional active ingredients selected from the non-limiting group of emulsifiers, mineral oils and / or waxes, vitamins, fragrances , dyes, essential oils, essential oils, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active ingredients, preservatives,
    BE2016 / 5508 antioxidants, vegetable oils, animal oils, solvents, vehicles, buffers, filler, UV protectants, natural extractions, antibiotics, anti-inflammatory agents, film former, deodorants, antihistamines, pigments, oxidizing agents, denaturants, reducing agents, detergents, penetrating agents, opacifying agents, binders, bleaches, chelating agent, skin protectants, keratolytic agents, masking agents, cleanser, foam enhancer, abrasive, sebum repellent, nail conditioner, depilatory, skin bleach, skin care, sugars and derivatives, viscosity regulators, emulsion stabilizer, moisturizers, emollients, emollient, emollient agents, fat moisturizers, moisturizers, skin softener, hydrotrope agent, humectants, plasticizers, analgesics, anti-acne agents, antiperspirants, thickeners, absorbers bentia, stabilizers, biocides, anti-foaming agents and surfactants.
    It goes without saying that the above list is not limitative and that all excepts known by a person skilled in the art can be added to a composition according to the present invention.
    In a preferred embodiment, the topical composition of the present invention comprises peruvian balm.
    In a preferred embodiment, a composition of the present invention comprises between 0.05 and 0.4 mass% peruvian balm, more preferably between 0.15 and 0.35 mass% peruvian balm, and most preferably between 0.2 and 0.3 mass% peruvian balm.
    In the present invention, the term peruvian balm refers to a resin recovered from the bark of the Myroxylon pereirae. Due to its various positive effects, it is often used as an additive or component in industrial products and food and / or medical compositions. Peruvian balm has, among other things, analgesic, itch-relieving, antiseptic, anti-fungal and anti-parasitic effects. Nevertheless, the use of peruvian balm in 2005 was not recommended in the European Union due to its high allergenicity and / or eczema-inducing character.
    However, a preferred composition of the present invention neutralizes the above-mentioned detrimental characteristics by an apparent synergistic effect between the abietic acid present and the peruvian balm. Thus, in several experiments evaluating the use of compositions of the present invention - see below - no case of allergy or eczema has yet been observed.
    BE2016 / 5508
    In addition, it was shown that the synergistic effect between (the source of) abietic acid and peruvian balm in a composition according to the present invention is the healing and treatment process in patients with certain skin conditions.
    In a preferred embodiment, the composition comprises a mineral, vegetable, animal or silicone oil as a base.
    In a more preferred embodiment, the composition comprises a mineral, vegetable, animal or silicone oil with an occlusive effect on the skin as a base.
    The addition of an oil with an occlusive effect on the skin as the basis of a composition according to the present invention ensures that the skin - after topical application of the composition - is closed off from the environment by a grease film. This protects the smeared skin surface from moisture and / or air, which considerably reduces the risk of infections. In addition, the occlusive effect of the mineral oil ensures that the active ingredients - present in the composition - are continuously supplied to the smeared skin surface and thus guarantee a long-term absorption of abietic acid.
    In a preferred embodiment, the present invention includes petrolatum as the basis for the composition. Petrolatum will close the skin very well after application.
    In a preferred embodiment, the present invention includes between 80 and 99 mass% petrolatum, and more preferably between 90 and 99 mass% petrolatum.
    A composition of the present invention can be formulated as a cream, gel, lotion, ointment, emulsion, suspension, solution, bath additive, film-forming agent, collodion, spray, powder, balm, foam or paste.
    Preferably, the composition is formulated as an ointment, cream, gel, lotion, emulsion or paste.
    In a preferred embodiment, the composition is produced by melting the source of abietic acid and then mixing it with the other excipients.
    In another embodiment, the composition is produced by grinding the source of abietic acid and then mixing it with the remaining excipients.
    It goes without saying that the present invention is by no means limited to the above-mentioned embodiments and / or excepients and that excepients are added or
    BE2016 / 5508 can be omitted in a composition according to application, conditions, allergies, etc.
    In a second aspect, the present invention relates to the use of a composition as described above in the treatment of skin conditions.
    In a preferred embodiment, the skin condition selected from the non-limiting list of xerosis, irritated skin, damaged skin, perniosis, skin fissures, acne, eczema, contact allergy, dermatitis, psoriasis, cold sores, chapped and / or dried lips, shingles, skin sores, pimples, blisters, pressure sores, rashes, transepidermal water loss, skin wounds, pressure sores, boils, skin aging, rosacea, stretch marks, etc.
    For example, it has been shown that treating the fingers and / or toes of perniosis patients, with a composition according to the present invention, has a positive and accelerating effect on the healing and treatment of perniosis.
    More specifically, the present invention induces an acceleration of the healing process of the aforementioned skin conditions by repairing the epidermal skin barrier in a first aspect and in a second aspect by a vasodilatory effect.
    Many skin conditions have been characterized by - sometimes invisible damage to the epidermal skin layer, leaving underlying layers unprotected and susceptible to infection. In addition, the epidermal skin membrane plays an important role in the degree of Transepidermal water loss (TEWL). TEWL is the amount of water released from the body - over the epidermal membrane - to the environment by diffusion and / or evaporation. It is evident that interruptions or damage to the respective membrane will increase TEWL and cause dehydration of the skin and body. Here it is postulated that the present invention provides accelerated repair of the epidermal membrane due to the presence of abietic acid. This property of abietic acid was previously unknown and naturally has a desirable effect in the treatment of one or more of the aforementioned skin conditions.
    In addition, it has been shown that abietic acid has a vasodilatory effect and thus directly improves blood flow. This function of abietic acid mainly plays a role in the treatment of perniosis. Perniosis is a direct result of narrowing of blood vessels in the hands and feet (~ Raynaud's phenomenon). The vasodilatory effect of abietic acid counteracts this vasoconstriction and thus reduces swelling, redness and itching, and warming of hands and / or
    BE2016 / 5508 feet of perniosis patients. In concrete terms, the present invention thus induces a faster and more efficient treatment of perniosis. Nevertheless, the vasodilatory effect of abietic acid also has an influence in the accelerated healing of other skin conditions. Blood vessels dilation - as a result of the abietic acid in the present invention - improves circulation, as mentioned before. As a result, the necessary molecules, components and nutrients that play a role in the healing process are supplied faster, more efficiently and possibly more locally. It is evident that this results in an accelerated healing and / or repair process.
    Another additional advantage of the present invention is the long shelf life due to the high degree of oiliness due to the large proportion of lipophilic components in a composition according to the present invention.
    In what follows, the invention is described by means of non-limiting examples illustrating the invention, which are not intended or are to be construed to limit the scope of the invention.
    EXAMPLES
    EXAMPLE 1a: Composition of an ointment for the treatment of perniosis
    An ointment has been formulated to treat perniosis. Affected ointment consists of the following ingredients (The INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are shown):
    Ingredient mass% Petrolatum 97.95 Poix de Bourgogne 1.76 Myroxylon pereirae resin 0.29
    After melting petrolatum, the Myroxylon pereirae resin and ground Poix de Bourgogne were added. Cooling the mixture resulted in the final ointment structure.
    EXAMPLE 1b: Double-blind experiment
    The ointment of Example 1a was subjected to a double-blind experiment to prove its effectiveness.
    For this, 10 patients with perniosis - with permission - were split into two groups of 5 patients and subjected to a double-blind experiment. The fingers
    BE2016 / 5508 and toes of the first group of perniosis patients were smeared daily with a topical composition according to the present invention, while the second group of patients were smeared daily with a similar composition but without a source of abietic acid (~ Poix de Bourgogne in the ointment according to example 1a). Patients were asked daily - for 7 days - about their discomforts - such as pain and itching - due to perniosis and to grade them relatively [1 to 10] from their original status [10]. In addition, skin redness and swelling were parameterized and evaluated by a researcher who had no knowledge of which patient belonged to which group (~ double-blind). The results are shown in tables 1a and 1b below.
    Table 1a - Results double-blind experiment from example 1b - ointment according to present invention from example 1a.
    P = patient, O = patient discomfort, Z = swelling as evaluated by investigator; R = redness as evaluated by investigator.
    Day PI P2 P3 P4 P5 Average 1 O 10 10 10 lioBOiiiio 10 10 z 10 10 10 lllllll! 10 10 R 10 10 10 10 10 10 2 O 8 8 6 8 7.4 z lllllll! 8 8 lllllllll 7 iiiiiiiiiiii R 8 Ί 7 5 7 7 111! 11111! 6 hhhlhhhh 11111111111! hhhh ^ hhhh 3 z lllllll 4 5 111111111 5 5.2 R 5 5 4 5 5 5.4 4 0 3 4 4 z iiiiiiii 3 4 lllllllll 2 iiiiiiiiiiii R 3 4 3 2 2 2.8 O 7 you Π ss « 5 z 2 1 2 111111111 1 1.6 R 1 2 1 0 1 1 O /// ^ // 1 1 3 6 z 1111-111 O 2 lllllllll O iiiiiliiiiii R 0 1 0 0 0 0.2 » O lllllll / ::::::::::::: 4 /: /: /: /: /: /: / :: 7 Z. 11111111 0 0 lllllllll 0 0.4 R 0 1 0 0 0 0.2
    Table 1b - Results double blind experiment from Example 1b - ointment without source of abietic acid from Example 1a
    P = patient, O = patient discomfort, Z = swelling as evaluated by investigator; R = redness as evaluated by investigator.
    Day
    PI io
    P2 io
    P3
    P4
    P5
    Average
    9.4
    BE2016 / 5508
    These results show that a composition according to the present invention induces a faster decrease in both discomfort, swelling and redness than a similar composition without a source of abietic acid (~ Poix de Bourgogne).
    Analogous double-blind experiments showed that a composition of the present invention also induced accelerated healing and / or hydration of the skin - compared to a similar composition with no source of abietic acid in patients with irritated skin, xerosis, skin splits and damaged skin. skin.
    EXAMPLE 2a: Composition of an ointment for the treatment of perniosis
    An ointment has been formulated to treat perniosis. The ointment in question consists of the following ingredients (The INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are shown):
    Ingredient mass% Paraffin 97.88 Colophonium (~ resin of Picea abies) 1.83 Myroxylon pereirae resin 0.29
    EXAMPLE 2b: Efficacy experiment of composition according to Example 2a
    A patient who has been suffering from skin splits and cracks in the hand skin as a result of crutch walking for two years has recently been treated with the composition according to example 2a. For this, the patient's hands were rubbed daily with the composition of Example 2a and the severity of the skin fissures was evaluated based on the number, width, length and depth of the skin fissures, and based on the patient's discomfort and pain. experienced.
    BE2016 / 5508
    Two days after the start of treatment, the patient no longer experienced any discomfort and the skin gaps and skin cracks were fully repaired. The patient's hands were rubbed for a further 12 days with the composition of Example 2a. No skin gaps or cracks in the hand skin were observed in the patient during these 12 days. In addition, the patient stated that he had not experienced any discomfort since the treatment.
    Treatment was discontinued two weeks after the initiation while the patient was further monitored on a daily frequency. The patient's hands again showed skin cracks and splits three days after treatment was discontinued.
    The affected patient was retreated with the composition of Example 2a and monitored daily. After two days, the cracks and fissures in the skin of the patient's hands had healed.
    This experiment shows that the present invention is effective not only in the treatment of skin cracks and fissures, but also an effective one in the prevention of fissures and cracks.
    EXAMPLE 3: Composition of a cream for the treatment of xerosis
    A cream has been formulated to treat xerosis. The cream in question consists of the following ingredients (The INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are shown):
    Ingredient mass% 0 Aqua 93.1 Petrolatum 4.95 Poix de Bourgogne 1.77 Myroxylon pereirae resin 0.25
    EXAMPLE 4: Composition of an emulsion for the treatment of skin fissures
    An emulsion was formulated to treat skin fissures. The emulsion concerned consists of the following ingredients (The INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are shown):
    Ingredient mass% Aqua 57.52
    BE2016 / 5508
    Zinc oxide paste 25.17 Polysorbate 60 5.03 Poix de Bourgogne 2.03 Myroxylon pereirae resin 0.25
    EXAMPLE 5: Composition of a gel for the treatment of damaged skin
    An emulsion was formulated to treat skin fissures. The gel in question consists of the following ingredients (The INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are shown):
    Ingredient mass% 0 Aqua 74.16 Glycerin 18.64 Polysorbate 60 3.74 Cellulose gum 1.18 Colophonium (~ resin of Picea abies) 2.01 Myroxylon pereirae resin 0.27
    EXAMPLE 6: Composition of a gel for the treatment of cracked lips
    A gel was formulated to treat cracked lips. The gel in question consists of the following ingredients (The INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are shown):
    Ingredient mass% Aqua 74.43 20 Glycerin 18.64 Polysorbate 60 3.74 Cellulose gum 1.20 Poix de Bourgogne 1.99
    EXAMPLE 7: Composition of a balm for the treatment of xerosis
    A balm was formulated to treat xerosis. The balm concerned consists of the following ingredients (The INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are shown):
    BE2016 / 5508
    Ingredient mass% Aqua 55.42 Petrolatum 32.89 Propylene glycol 5.23 Polysorbate 50 2.04 Colophonium (~ resin of Picea abies) 1.97 Lemon oil 1.18 5 Myroxylon pereirae resin 0.27
    It is believed that the present invention is not limited to the embodiments described above and that some modifications or changes to the described examples can be added without revaluating the added claims.
    EXAMPLE 8: Composition of a cream for the treatment of perniosis
    A cream has been formulated to treat perniosis. The cream in question consists of the following ingredients (The INCI names (International Nomenclature of
    Cosmetic Ingredients) of the ingredients are shown):
    Ingredient mass% Aqua 89.57 Petrolatum 7.9920 Poix blanche 2.05 Myroxylon pereirae resin 0.28
    EXAMPLE 9: Composition of an ointment for the treatment of xerosis
    An ointment has been formulated to treat xerosis. The ointment in question consists of the following ingredients (The INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are shown):
    BE2016 / 5508
    Ingredient mass% Petrolatum 97.75 Turpentine 1.96 Myroxylon pereirae resin 0.29
    EXAMPLE 10: Composition of a cream for the treatment of dermatitis
    A cream has been formulated to treat dermatitis. The cream in question consists of the following ingredients (The INCI (International Nomenclature of Cosmetic Ingredients) names of the ingredients are shown):
    Ingredient mass% Aqua 82.16 Petrolatum 15.50 Abietic acid 2.06 Myroxylon pereirae resin ozzs 15
    BE2016 / 5508
    权利要求:
    Claims (8)
    [1]
    CONCLUSIONS
    A topical composition comprising a source of abietic acid or an ester or salt thereof as the active ingredient, for use in treatment of perniosis.
    [2]
    Topical composition according to claim 1, characterized in that the abietic acid source is a Picea abies resin, said resin being distilled or heated and filtered after mining.
    [3]
    Topical composition according to claim 2, characterized in that the resin derived from Picea abies is present in a concentration of 0.1 to 50% by mass.
    [4]
    Topical composition according to claim 3, characterized in that the source of abietic acid is Poix de Bourgogne.
    [5]
    Topical composition according to any one of the preceding claims further comprising auxiliaries or additional active ingredients selected from the non-limiting group of emulsifiers, mineral oils and / or waxes, vitamins, fragrances, dyes, essential oils, essential oils, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active ingredients, preservatives, antioxidants, vegetable oils, animal oils, solvents, vehicles, buffers, filler, UV protectants, natural extractions, antibiotics, anti-inflammatory agents, film-former, deodorants, antihistamines, pigments, oxidizing agents, denaturant, reducing agents, detergents, penetration enhancers , opacifiers, binders, bleaches, chelating agents, skin protectants, keratolytic agents, masking agents, cleanser, foam enhancer, abrasive, sebum, nail conditioner, depilatory, skin bleach, skin care and, sugars and derivatives, viscosity regulators, emulsion stabilizer, wetting agents, emollients, skin tanning, toning, freshener, emollients, fat moisturizers, moisturizers, skin softener, hydrotrope, humectants, plasticizers, pain relievers, anti-acne agents, antiperspirants , absorbents, stabilizers, biocides, anti-foaming agents and surfactants.
    [6]
    Topical composition according to any of the preceding claims, further comprising between 70 and 99 mass% petrolatum.
    [7]
    The topical composition of any of the preceding claims further comprising between 0.05 and 0.40 mass% of a resin of Myroxylon pereirae.
    [8]
    Topical composition according to any of the preceding claims, wherein the composition consists of:
    a. between 90 and 99 mass% petrolatum
    BE2016 / 5508
    b. between 0.05 and 0.40 mass% resin of Myroxylon pereirae
    c. between 0.5 and 10% by mass of a source of abietic acid or a salt or an ester thereof.
    BE2016 / 5508
    COMPOSITION FOR TREATMENT OF PERNIOSIS
    类似技术:
    公开号 | 公开日 | 专利标题
    DE60130466T2|2008-06-12|ANTIPRURITIC COMPOSITIONS AND WOUND HEALING COMPOSITIONS
    NO933092L|1993-10-29|Therapeutic and cosmetic compositions for the treatment of skin
    Mishra et al.2014|Formulation and evaluation of herbal antioxidant face cream of Nardostachys jatamansi collected from Indian Himalayan region
    Akhoondinasab et al.2015|Assessing effect of three herbal medicines in second and third degree burns in rats and comparison with silver sulfadiazine ointment
    WO2017037534A1|2017-03-09|Topical compositions for treatment of psoriasis
    JP2006520769A|2006-09-14|Skin care products containing tall oil fatty acids and vegetable oils for dry and scaled skin and for the treatment of psoriasis, dermatitis, and eczema
    US20100080861A1|2010-04-01|Cosmetic or dermatological compositions comprising a mixture of essential oils, and its uses thereof, particularly for the care of sensitive or sensitized skin
    Rai et al.2019|Pharmaceutical Creams and their use in wound healing: A Review
    Raharivelomanana et al.2018|Tamanu oil and skin active properties: from traditional to modern cosmetic uses
    US9498505B2|2016-11-22|Embelia concinna extract comprising flavonoids in cosmetic and pharmaceutical compositions
    BE1024364B1|2018-02-05|COMPOSITION FOR TREATMENT OF SKIN DISEASES
    US20020176876A1|2002-11-28|Topical therapeutic skin care system
    JP6983160B2|2021-12-17|A composition comprising ambora extract and green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus, and senile pruritus.
    CN104188808A|2014-12-10|Freckle and chloasma removing gel and preparation method thereof
    WO2004096119A2|2004-11-11|Topical pharmaceutical compositions, methods of manufacture thereof and articles of manufacture containing same
    RU2683248C1|2019-03-27|Lotion composition for care after shaving the face skin with acne
    KR20170092281A|2017-08-11|Cosmetic Composition for Improving Acnes Using Chamomile
    CA2627021A1|2009-10-10|Combination natural source/local anesthetic/dual component penetration enhancer topical formulation useful for treating pain, itching and/or inflammation of the skin
    JP2021509123A|2021-03-18|Topical skin care composition
    KR20110049201A|2011-05-12|The facewashing comestic composition and its extraction method improving etiology of acnegenic skin
    EP0697878B1|1998-09-16|New use of equisetum
    WO2017197535A1|2017-11-23|Product for the therapy and prevention of burnout syndrome of the scalp and the skin
    JP3792745B2|2006-07-05|Tyrosinase inhibitor
    EP1688145A1|2006-08-09|Methods and compositions for treating psoriasis
    CN107174562A|2017-09-19|A kind of cosmetics and skincare product
    同族专利:
    公开号 | 公开日
    NL2018740B1|2018-01-05|
    BE1024364A1|2018-01-30|
    BE1024364B9|2018-03-07|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB2440601A|2006-08-05|2008-02-06|Julie Ann Mitchell|Cream formulations|
    WO2009027823A2|2007-08-29|2009-03-05|Ramirez D'onofrio, Alvaro D.|Pharmaceutical composition for selective stimulation of wound healing processes, dermal-epidermal normal tissular trophism processes, its preparation and application.|
    JP2014114251A|2012-12-11|2014-06-26|Kao Corp|Ceramide production promoter|
    法律状态:
    2018-02-28| FG| Patent granted|Effective date: 20180205 |
    优先权:
    申请号 | 申请日 | 专利标题
    BE20165508A|BE1024364B9|2016-06-29|2016-06-29|COMPOSITION FOR TREATMENT OF PERNIOSIS|BE20165508A| BE1024364B9|2016-06-29|2016-06-29|COMPOSITION FOR TREATMENT OF PERNIOSIS|
    NL2018740A| NL2018740B1|2016-06-29|2017-04-19|COMPOSITION FOR TREATMENT OF SKIN DISEASES|
    [返回顶部]